Table 1.

C 825 T genotype distribution

TotalCCCTTTP
n (%) total341170 (49.8)144 (42.2)27 (7.9)
Oral cavity205 (25.0)12 (60.0)3 (15.0)
Oropharynx10864 (59.3)35 (32.4)9 (8.3)
Hypopharynx4923 (46.9)25 (51.0)1 (2.0)
Larynx15073 (48.7)66 (44.0)11 (7.3)
Multiple sites145 (35.7)6 (42.9)3 (21.4)0.033
Mean age (y ± SD)61.8 ± 12.161.2 ± 10.762.1 ± 13.863.6 ± 10.70.315
Median follow up, mo (range)61 (3-143)65 (3-128)57 (6-143)38 (6-97)0.018*
Gender (m/f)286/55137/33129/1520/70.496
Smoking, n (%)321 (90.0)152 (49.5)131 (42.7)24 (7.8)0.724
Pack years46.6 ± 22.545.4 ± 21.246.2 ± 23.256.0 ± 25.70.101
AJCC
    I5322 (41.5)27 (50.9)4 (7.5)
    II5025 (50.0)21 (42.0)4 (8.0)
    III5527 (49.1)22 (40.0)6 (10.9)
    IVA15782 (52.2)62 (39.5)13 (8.3)
    IVB2312 (52.2)11 (47.8)0 (0)
    IVC32 (66.7)1 (33.3)0 (0)0.866
Grade
    1218 (38.1)11 (52.4)2 (9.5)
    2246116 (47.2)109 (44.3)21 (8.5)
    3-47446 (62.2)24 (32.4)4 (5.4)0.170
  • NOTE: C825T genotype distribution with regard to tumor site, demographic characteristics, primary therapy, tumor stage (AJCC), and histologic grading in 341 patients with HNSCC.

  • * Kruskal Wallis Test.